Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells
- PMID: 20623193
- DOI: 10.1007/s10495-010-0525-5
Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells
Abstract
TNF-related apoptosis-inducing ligand (TRAIL, Apo2L) is a promising anticancer agent with high specificity for cancer cells. Many strategies have been proposed to enhance the sensitivity of cancer cells to TRAIL-mediated apoptosis, including the use of combination treatment with conventional cancer therapies. However, few reports have evaluated the effects of TRAIL in combination with mechanical stress, which can also cause apoptosis of cancer cells. In the present study, we describe a custom-designed culture system that delivers two atmospheres of elevated pressure (EP) by using compressed air, and which enhances the sensitivity of cancer cells to TRAIL-mediated apoptosis. The combination of TRAIL and EP significantly increased apoptosis of human H460 lung cancer cells more than hyperbaric normoxia or normobaric mild hyperoxia. EP-potentiating TRAIL-mediated apoptosis of H460 cells was accompanied by up-regulated death receptor 5 (DR5), activation of caspases, decreased mitochondrial membrane potential, and reactive oxygen species production. We also observed EP-induced sensitization of TRAIL-mediated apoptosis in other cancer cell types. In contrast, human normal cells showed no DNA damage or cell death when exposed to the combined treatment. In a chicken chorioallantoic membrane model, EP enhanced TRAIL-mediated apoptosis of tumors that developed from transplanted H460 cells. Collectively, EP enhanced TRAIL-induced apoptosis of human lung carcinoma cells in vitro and in vivo. These findings suggest that EP is a mechanical and physiological stimulus that might have utility as a sensitizing tool for cancer therapy.
Similar articles
-
Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.Cancer Res. 2006 Jun 1;66(11):5867-74. doi: 10.1158/0008-5472.CAN-05-3544. Cancer Res. 2006. PMID: 16740726
-
Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.Cancer Res. 2000 Dec 15;60(24):7149-55. Cancer Res. 2000. PMID: 11156424
-
Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.Oncol Rep. 2007 Jan;17(1):175-84. Oncol Rep. 2007. PMID: 17143496
-
TRAIL receptor signaling and therapeutics.Expert Opin Ther Targets. 2010 Oct;14(10):1091-108. doi: 10.1517/14728222.2010.519701. Expert Opin Ther Targets. 2010. PMID: 20819019 Review.
-
TRAIL as a target in anti-cancer therapy.Cancer Lett. 2009 Nov 18;285(1):1-5. doi: 10.1016/j.canlet.2009.02.029. Epub 2009 Mar 18. Cancer Lett. 2009. PMID: 19299078 Review.
Cited by
-
Magnetic Field Changes Macrophage Phenotype.Biophys J. 2018 Apr 24;114(8):2001-2013. doi: 10.1016/j.bpj.2018.03.002. Biophys J. 2018. PMID: 29694876 Free PMC article.
-
Multiple Interactions Between Cancer Cells and the Tumor Microenvironment Modulate TRAIL Signaling: Implications for TRAIL Receptor Targeted Therapy.Front Immunol. 2019 Jul 3;10:1530. doi: 10.3389/fimmu.2019.01530. eCollection 2019. Front Immunol. 2019. PMID: 31333662 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources